UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Explaining multivariate molecular diagnostic tests via Shapley values

BMC medical informatics and decision making, 2021-07, Vol.21 (1), p.1-211, Article 211

2021

Volltextzugriff (PDF)

Improving the power of gene set enrichment analyses

BMC bioinformatics, 2019-05, Vol.20 (1), p.257-257, Article 257

2019

Volltextzugriff (PDF)

A dropout-regularized classifier development approach optimized for precision medicine test discovery from omics data

BMC bioinformatics, 2019-06, Vol.20 (1), p.325-325, Article 325

2019

Volltextzugriff (PDF)

Robust identification of molecular phenotypes using semi-supervised learning

BMC bioinformatics, 2019-05, Vol.20 (1), p.273-273, Article 273

2019

Volltextzugriff (PDF)

Mass Spectrometry-Based Multivariate Proteomic Tests for Prediction of Outcomes on Immune Checkpoint Blockade Therapy: The Modern Analytical Approach

International journal of molecular sciences, 2020-01, Vol.21 (3), p.838

2020

Volltextzugriff (PDF)

Exact Shapley values for local and model-true explanations of decision tree ensembles

Machine learning with applications, 2022-09, Vol.9, p.100345, Article 100345

2022

Volltextzugriff (PDF)

Semi-Quantitative MALDI Measurements of Blood-Based Samples for Molecular Diagnostics

Molecules (Basel, Switzerland), 2022-02, Vol.27 (3), p.997

2022

Volltextzugriff (PDF)

The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients

BMC cancer, 2018-03, Vol.18 (1), p.310-310, Article 310

2018

Volltextzugriff (PDF)

Molecular and translational biology of the blood-based VeriStrat® proteomic test used in cancer immunotherapy treatment guidance

Journal of mass spectrometry and advances in the clinical lab, 2023-11, Vol.30, p.51-60

2023

Volltextzugriff (PDF)

Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations

Journal for immunotherapy of cancer, 2019-03, Vol.7 (1), p.91-91, Article 91

2019

Volltextzugriff (PDF)

831 Exact Shapley values for explaining complex machine learning based molecular tests of checkpoint inhibitors: potential utility for patients, physicians, and translational research

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A870-A871

2021

Volltextzugriff (PDF)

26 Validation of the Primary Immune Response (PIR) test in advanced non-small cell lung cancer (NSCLC): blinded retrospective analyses from the POPLAR and OAK trials

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A30-A31

2021

Volltextzugriff (PDF)

28 Predictions of outcomes and benefit of immune checkpoint inhibitor treatment in NSCLC require information on both tumor and host biology

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A33-A33

2021

Volltextzugriff (PDF)

Detection of Tumor Epidermal Growth Factor Receptor Pathway Dependence by Serum Mass Spectrometry in Cancer Patients

Cancer epidemiology, biomarkers & prevention, 2010-02, Vol.19 (2), p.358-365

2010

Volltextzugriff (PDF)

ITOC2 – 036. A method for developing predictive tests for immunotherapy benefit

European journal of cancer (1990), 2015-03, Vol.51, p.S12-S13

2015

Volltextzugriff (PDF)

Retrospective validation of a pretreatment serum protein profile in metastatic non-small cell lung cancer patients treated with a pembrolizumab containing regime as first line of treatment

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e21135-e21135

2021

Volltextzugriff (PDF)

Prognostic and Predictive Role of the VeriStrat Plasma Test in Patients with Advanced Non–Small-Cell Lung Cancer Treated with Erlotinib or Placebo in the NCIC Clinical Trials Group BR.21 Trial

Journal of thoracic oncology, 2012-11, Vol.7 (11), p.1653-1660

2012

Volltextzugriff (PDF)

Predicting prognosis in COVID-19 patients using machine learning and readily available clinical data

International journal of medical informatics (Shannon, Ireland), 2021-11, Vol.155, p.104594-104594, Article 104594

2021

Volltextzugriff (PDF)

A Serum Protein Classifier Identifying Patients with Advanced Non-Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint Inhibitors

Clinical cancer research, 2020-10, Vol.26 (19), p.5188-5197

2020

Volltextzugriff (PDF)

Abstract 599: A panel of mass spectrometry based serum protein tests for predicting graft-versus-host disease (GvHD) and its severity

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.599-599

2015

Volltextzugriff (PDF)

Abstract 210: Development of scores reflective of biological processes underlying human disease states from mass spectrometry of serum

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.210-210

2017

Volltextzugriff (PDF)

Abstract 4530: An independent validation of a screening test using mass spectrometry for detection of hepatocellular carcinoma

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.4530-4530

2019

Volltextzugriff (PDF)

Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy

Lung cancer (Amsterdam, Netherlands), 2018-03, Vol.117, p.64-69

2018

Volltextzugriff (PDF)

Abstract 5527: Serum proteomic scores for understanding the mechanisms of immune-related adverse events (irAEs) in non-small cell lung cancer

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.5527-5527

2020

Volltextzugriff (PDF)

1 – 25 von 66

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(63)
Mit Volltextzugriff
(65)

Publikationsform

Artikel
(66)

Sprache

Englisch
(66)

Erscheinungsjahr

n.n

Thema

Science & Technology
(34)
Life Sciences & Biomedicine
(32)
Oncology
(16)
Humans
(15)
Proteomics
(15)
Biomarkers
(13)
Male
(11)
Female
(10)
Mass Spectrometry
(10)
Immunotherapy
(9)
Patients
(9)
Cancer Therapies
(8)
Classification
(8)
Lung Cancer
(8)
Machine Learning
(8)
Tumors
(8)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(7)
Chemotherapy
(7)
Lung Neoplasms - Drug Therapy
(7)
Prognosis
(7)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Explaining multivariate molecular diagnostic tests via Shapley values

Improving the power of gene set enrichment analyses

A dropout-regularized classifier development approach optimized for precision medicine test discovery from omics data

Robust identification of molecular phenotypes using semi-supervised learning

Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial

Mass Spectrometry-Based Multivariate Proteomic Tests for Prediction of Outcomes on Immune Checkpoint Blockade Therapy: The Modern Analytical Approach

Exact Shapley values for local and model-true explanations of decision tree ensembles

Semi-Quantitative MALDI Measurements of Blood-Based Samples for Molecular Diagnostics

The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients

Molecular and translational biology of the blood-based VeriStrat® proteomic test used in cancer immunotherapy treatment guidance

Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations

831 Exact Shapley values for explaining complex machine learning based molecular tests of checkpoint inhibitors: potential utility for patients, physicians, and translational research

26 Validation of the Primary Immune Response (PIR) test in advanced non-small cell lung cancer (NSCLC): blinded retrospective analyses from the POPLAR and OAK trials

28 Predictions of outcomes and benefit of immune checkpoint inhibitor treatment in NSCLC require information on both tumor and host biology

Detection of Tumor Epidermal Growth Factor Receptor Pathway Dependence by Serum Mass Spectrometry in Cancer Patients

ITOC2 – 036. A method for developing predictive tests for immunotherapy benefit

Retrospective validation of a pretreatment serum protein profile in metastatic non-small cell lung cancer patients treated with a pembrolizumab containing regime as first line of treatment

Prognostic and Predictive Role of the VeriStrat Plasma Test in Patients with Advanced Non–Small-Cell Lung Cancer Treated with Erlotinib or Placebo in the NCIC Clinical Trials Group BR.21 Trial

Predicting prognosis in COVID-19 patients using machine learning and readily available clinical data

A Serum Protein Classifier Identifying Patients with Advanced Non-Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint Inhibitors

Abstract 599: A panel of mass spectrometry based serum protein tests for predicting graft-versus-host disease (GvHD) and its severity

Abstract 210: Development of scores reflective of biological processes underlying human disease states from mass spectrometry of serum

Abstract 4530: An independent validation of a screening test using mass spectrometry for detection of hepatocellular carcinoma

Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy

Abstract 5527: Serum proteomic scores for understanding the mechanisms of immune-related adverse events (irAEs) in non-small cell lung cancer

Suchergebnisse filtern